Nuvectis Pharma, Inc. Stock Price, News & Analysis

Nuvectis Pharma (NASDAQ: NVCT) announced poster presentations for its investigational candidate NXP900 at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, MA, taking place October 22–26, 2025.

Two posters will appear in Poster Session A on October 23, 2025, 12:30–4:00 PM ET: LB-A019 covering clinical safety, pharmacokinetics, pharmacodynamics, and cytochrome P450 interactions (presenter Gerald Falchook, MD), and A099 reporting that NXP900 potently inhibits tumor growth in FAT1‑mutated xenograft models (presenter Asier Unciti‑Broceta).

Nuvectis Pharma (NASDAQ: NVCT), a clinical-stage biopharmaceutical company, has appointed Dr. Juan Sanchez to its Board of Directors. Dr. Sanchez most recently served as VP of Corporate Communications and Investor Relations at Intra-Cellular Therapies, which was acquired by Johnson & Johnson for $14.6 billion in April 2025.

Dr. Sanchez brings over 30 years of experience spanning patient care, Wall Street research analysis, and biopharmaceutical executive leadership. His appointment comes as Nuvectis prepares to initiate its Phase 1b program for NXP900, targeting advanced and treatment-resistant cancers.

Nuvectis Pharma (NASDAQ: NVCT), a clinical-stage biopharmaceutical company specializing in precision oncology medicines, has announced its participation in the H.C. Wainwright Global Investment Conference.

Chairman and CEO Ron Bentsur will deliver a corporate presentation that will be available for on-demand viewing by conference attendees starting September 5, 2025, at 7:00 a.m. ET. The company will also participate in virtual one-on-one meetings during the conference, which runs from September 8-10, 2025.

Nuvectis Pharma (NASDAQ: NVCT) has announced the initiation of its Phase 1b program for NXP900, following successful completion of dose escalation and drug-drug interaction studies. The program consists of two components: a single-agent study evaluating NXP900 in patients with specific genetic alterations, and a combination study with EGFR and ALK inhibitors in NSCLC patients who developed treatment resistance.

The single-agent component targets patients with YES1 amplification, FAT1 mutations in NSCLC, NF2 mutations in mesothelioma and renal cancer, and other solid tumors with relevant Hippo Pathway alterations. The combination study, expected to start later in 2025, will focus on NSCLC patients who developed resistance to existing treatments.

Nuvectis Pharma (NASDAQ: NVCT) reported significant progress in Q2 2025, highlighted by the successful completion of NXP900's Phase 1a dose escalation study in advanced solid tumors and a drug-drug interaction study in healthy volunteers. The company strengthened its financial position with a proforma cash balance of $39 million as of June 30, 2025, following an ATM share acquisition by a healthcare-focused institutional investor in July.

The company reported a net loss of $6.3 million for Q2 2025, compared to $4.4 million in Q2 2024. R&D expenses increased to $3.6 million, while G&A expenses rose to $3.0 million. The current cash position is expected to fund operations into second half of 2027, with plans to initiate the NXP900 Phase 1b program imminently and explore NXP800's potential in endometrial and prostate cancers.

Nuvectis Pharma (NASDAQ: NVCT) has announced final clinical data from two key studies. The NXP800 Phase 1b study in ovarian cancer showed mixed results with 2 partial responses and 3 stable diseases among 13 evaluable patients with recurrent, platinum-resistant, ARID1a-mutated ovarian cancer. While demonstrating biological activity, the company will discontinue development in ovarian cancer but explore opportunities in other cancers.

The company also reported successful completion of the NXP900 Phase 1a dose escalation study and drug-drug interaction study. The Phase 1a study evaluated doses from 20 to 300 mg/day, showing mainly mild to moderate gastrointestinal side effects and approximately 90% inhibition of SRC kinase phosphorylation at doses ≥150 mg/day. The Phase 1b program for NXP900, both as monotherapy and in combination with other anti-cancer agents, is expected to begin in the coming weeks.

Nuvectis Pharma (NASDAQ: NVCT) has successfully completed a drug-drug interaction (DDI) study for NXP900 in healthy volunteers. The study revealed that NXP900 is classified as a weak inhibitor of CYP3A, supporting its potential combination with EGFR and ALK inhibitors in non-small cell lung cancer (NSCLC) treatment.

The study involved 14 healthy volunteers and showed NXP900 increased Midazolam concentration by less than 2-fold. No serious adverse events were reported, with only mild to moderate diarrhea and non-infection related white blood cell count increases observed.

The company is completing its Phase 1a dose escalation study and plans to advance to Phase 1b testing, which will evaluate NXP900 both as a single agent and in combinations with leading EGFR and ALK drugs in patients whose cancers may be sensitive to SRC/YES1 inhibition.

Nuvectis Pharma (NASDAQ: NVCT), a clinical-stage biopharmaceutical company specializing in precision medicines for oncology, has announced its participation in the upcoming 3rd Annual H.C. Wainwright Global BioConnect Investor Conference. Ron Bentsur, the company's Chairman and CEO, will deliver a presentation on May 20th, 2025, from 10:30 to 11:00 a.m. ET. The presentation will be accessible via webcast for interested investors and stakeholders.

Nuvectis Pharma reported its Q1 2025 financial results and business updates. The company presented promising NXP900 Phase 1a clinical data at AACR 2025, showing robust pharmacodynamic response and acceptable safety in advanced cancer patients. Nuvectis completed a $15.5M financing, extending cash runway into Q1 2027. Financial highlights include: cash position of $29.9M as of March 31, 2025 (up from $18.5M in December 2024), and a net loss of $5.3M (vs $4.2M in Q1 2024). R&D expenses were $3.7M, while G&A expenses reached $1.9M. The company is preparing for NXP900's Phase 1b study and continues enrollment in the NXP800 Phase 1b trial for platinum-resistant, ARID1a mutated ovarian cancer, with updates expected in the coming months.